MedTest Announces Availability of a Hydrocodone Assay for Urine Drug Screening
Jun 1, 2016 - press releases
(Canton, Michigan) MedTest announced today the availability of a hydrocodone assay for use as an open-channel reagent or for use on the BS-200 and BS-480 Chemistry Analyzers for urine drug screening. The addition of hydrocodone broadens MedTest’s menu of urine drug screening reagents already available.
Hydrocodone is a semi-synthetic opioid derived from codeine and thebaine. It is used to relieve moderate to severe pain and to treat a cough. Hydrocodone is prescribed predominantly in the United States. Commercial Hydrocodone preparations are often combined with another medication to increase efficacy and reduce adverse effects. It is available as combination drugs with Acetaminophen such as Vicodin and Lortab, Ibuprofen (Vicoprofen) and antihistamines (Hyconine). In recent years, an increase in the abuse of the prescription pain management drugs Hydrocodone and Hydromorphone has been observed. Hydrocodone is rapidly metabolized to Hydromorphone and its glucuronide, and can be found in human urine for up to 2-3 days.
Hanjoon Ryu, CEO of MedTest, stated: “Hydrocodone is rapidly metabolized to hydromorphone and its glucuronide. Since it does not metabolize into morphine, standard opiate testing reagents will not detect its presence. Physicians request the hydrocodone test to effectively manage their patients and insure that they are getting a total picture of the patient’s medication status. Adding hydrocodone to our broad menu of urine drugs of abuse reagents is of value to the physician.”
About MedTest: MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing. In June 2013, MedTest acquired Pointe Scientific, a company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981. In the fall of 2014, MedTest acquired Clinitox Diagnostix, a company that manufactures and supports drug confirmatory testing via Liquid Chromatography/Mass Spectrometry (LC/MS).
For additional information:
|Debbie Whitehair, MT(ASCP)SC|
|Vice President, Marketing|